An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer
OBJECTIVES: I. Determine the effectiveness and safety of epoetin alfa in patients receiving
adjuvant chemotherapy for stage I, II, or III breast cancer. II. Determine the clinical
outcomes in these patients receiving this drug.
OUTLINE: This is a multicenter study. Patients receive epoetin alfa subcutaneously once
weekly for up to 24 weeks in the absence of unacceptable toxicity. Quality of life is
assessed at baseline, at week 13, and at study completion.
PROJECTED ACCRUAL: A maximum of 2,500 patients will be accrued for this study.
Primary Purpose: Supportive Care
John A. Glaspy, MD, MPH
Jonsson Comprehensive Cancer Center
United States: Federal Government